Atousa Hakamifard

Dr. Atousa Hakamifard


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Journal of Medical Mycology
Verified
Journal Article
Closed access
AHAtousa Hakamifard
Atousa Hakamifard
MHMarzieh Hashemi
Marzieh Hashemi
HFHamed Fakhim
Hamed Fakhim
SAShima Aboutalebian
Shima Aboutalebian
SHSomayeh Hajiahmadi
Somayeh Hajiahmadi
RMRasoul Mohammadi
Rasoul Mohammadi

3 January 2018 in Mycoses
Verified
Journal Article
Closed access
PDF file
RMRasoul Mohammadi
Rasoul Mohammadi
AMAbdolrasoul Mohammadi
Abdolrasoul Mohammadi
FAFereshteh Ashtari
Fereshteh Ashtari
FKFarzin Khorvash
Farzin Khorvash
AHAtousa Hakamifard
Atousa Hakamifard
Hamid BadaliHamid Badali
Hamid Badali

6 May 2023 in Pathology - Research and Practice
Verified
Journal Article
Closed access
RAReza Asemi
Reza Asemi
NNNesa Rajabpoor Nikoo
Nesa Rajabpoor Nikoo
ZAZatollah Asemi
Zatollah Asemi
RSRana Shafabakhsh
Rana Shafabakhsh
MHMohammad Hajijafari
Mohammad Hajijafari
AHAtousa Hakamifard
Atousa Hakamifard

9 March 2022 in Dermatologic Therapy
Verified
Journal Article
Closed access
MMMasoud Mardani
Masoud Mardani
SMSayna Mardani
Sayna Mardani
ZKZahra Asadi Kani
Zahra Asadi Kani
AHAtousa Hakamifard
Atousa Hakamifard

16 March 2021 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
SASara Abolghasemi
Sara Abolghasemi
AHAtousa Hakamifard
Atousa Hakamifard
SSSomayeh Sharifynia
Somayeh Sharifynia
MTMihan Pourabdollah Toutkaboni
Mihan Pourabdollah Toutkaboni
HTHamed Azhdari Tehrani
Hamed Azhdari Tehrani
Case reports of CAPA emerged. In most of the reports, the predominant species is Aspergillus fumigatus. Uncommon species are less reported. Due to poor clinical outcome with Aspergillus terreus, the increasing reports with this agent require attention.

1 March 2021
Verified
Journal Article
Open access
PDF file
BABahareh Abtahi-Naeini
Bahareh Abtahi-Naeini
SHSajjad Hadian
Sajjad Hadian
FSFatemeh Sokhanvari
Fatemeh Sokhanvari
AHAmirali Hariri
Amirali Hariri
JVJaleh Varshosaz
Jaleh Varshosaz
AHAtousa Hakamifard
Atousa Hakamifard
The treatment of Cutaneous Leishmaniasis (CL) is complex, and the search for safer, more efficient, and cost-effective treatments is ongoing. This study aimed to evaluate the efficacy of the combination of liposomal and oral azithromycin as the first clinical study against CL. This assessor-blind, randomized clinical trial was conducted in out-patients Leishmaniasis clinic of Skin Diseases and Leishmaniasis. The cutaneous lesions of eligible participants were randomized to receive either oral azithromycin or the combined oral and topical liposomal azithromycin. All participants received 250 mg of azithromycin twice daily or 8 mg/per kg for 4 weeks. In the combination group, a topical liposomal formulation of 0.04 mmol/mL of azithromycin was administered as 0.2-0.5 cc twice daily according to the lesion size in order to make a thin layer of the drug on the surface of the lesion. The size and induration changes from baseline to the end of the study were analyzed. Twenty-one lesions of 13 patients in the combination group and 20 lesions of 14 patients in the oral group were recruited. The mean ± SD of improvement was significantly different between two groups after 12 weeks (3.89 ± 0.46 vs. 3.15 ± 1.23 P = 0.02 combination group vs. oral group respectively). The patients did not experience any systemic adverse effects related to azithromycin and the only adverse effects related to topical treatment were mild pruritus in 2 cases. In conclusion, the combination of oral and topical liposomal formulation of azithromycin is safe and effective to treat CL.